Bevacizumab PK and VEGF165 target binding
A population QSS-TMDD model coupling bevacizumab disposition to VEGF165 turnover, free antibody, target-bound complex, and total circulating VEGF165.
- Therapeutic
- Bevacizumab
- Target
- VEGFA, VEGF165, vascular endothelial growth factor A
- Disease
- Metastatic colorectal cancer
Biological model
A population QSS-TMDD model coupling bevacizumab disposition to VEGF165 turnover, free antibody, target-bound complex, and total circulating VEGF165.
Intervention
Bevacizumab
Biological focus
VEGFA, VEGF165, vascular endothelial growth factor A
Context
Metastatic colorectal cancer
Model details
A population QSS-TMDD model coupling bevacizumab disposition to VEGF165 turnover, free antibody, target-bound complex, and total circulating VEGF165.
Modeled states
- AUC total mg day Lmg*day/L
Modeled dynamic state for auc total mg day l.
- A peripheral free mgmg
Modeled dynamic state for a peripheral free mg.
- A total central mgmg
Modeled dynamic state for a total central mg.
- R total nMnM
Modeled dynamic state for r total nm.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
Key readouts
- Total bevacizumabunknown
Model-derived readout for total bevacizumab.
- Free bevacizumabunknown
Model-derived readout for free bevacizumab.
- Bevacizumab–VEGF165 complexunknown
Model-derived readout for bevacizumab–vegf165 complex.
- Total VEGF165unknown
Model-derived readout for total vegf165.
- Cumulative total exposuremg*day/L
Model-derived readout for cumulative total exposure.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
5 mg/kg every 2 weeks 70 kg deterministic simulation
How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations? Explore this intervention regimen through Total bevacizumab, Free bevacizumab, Bevacizumab–VEGF165 complex, Total VEGF165, Cumulative total exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations?
CL L day
Model parameter controlling cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsCancer Chemotherapy and Pharmacology
